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ABSTRACT 
Objectives: To assess the prevalence of vancomycin-resistant 
enterococcal rectal colonization in a 750.bed hospital (includ- 
ing assessment of the impact of antibiotic use on prevalence) 
and to compare this method of surveillance to that of monitor- 
ing sterile body fluid cultures. 
Design: A rectal swab culture survey was conducted on a ran- 
domly chosen sample of 131 patients who were stratified by 
prior antibiotic use. 
Results: The rectal swab culture survey indicated that a minimum 
of 6.2% of patients were colonized with vancomycin-resistant 
enterococcal, whereas monitoring sterile body fluid cultures 
indicated that 0.4% of patients were infected or colonized with 
vancomycin-resistant enterococci. Oral vancomycin therapy, 
parenteral vancomycin therapy, and cephalosporin therapy 
(cefoxitin, ceftriaxone, and ceftazidime) were associated with 
significantly increased risk of vancomycin-resistant enterococcal 
rectal colonization. 
Conc/usions: Periodic rectal swab culture surveys are more sen- 
sitive in detecting the prevalence of vancomycin-resistant entero- 
coccal colonization and can provide strategic information to 
guide infection control activities. Restriction of oral and par- 
enteral vancomycin therapy as well as restriction of cephalosporin 
therapy (cefoxitin, ceftriaxone, and ceftazidime) may contribute 
significantly to reducing the prevalence of vancomycin-resis- 
tant enterococcal colonization. 
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Since first reported in 1988, vancomycin-resistant entero- 
cocci (VRE) have rapidly disseminated and have been 
reported with increasing frequency from Belgium, France, 
Germany Italy, The Netherlands, Spain, the United Kingdom, 
and the United States.’ In the United States, the percentage 
of nosocomial enterococcal infections reported to the 
Centers for Disease Control (CDC) National Nosocomial 
Infections Surveillance System, from 1989 to 1993, that 
were caused byVF@ increased from 0.3% to 7.9%.‘By 1993, 
a regional survey established that VRE had been isolated 
from 31 hospitals in 14 states,3 and subsequent reports 
documented numerous hospital outbreaks of LWL4-’ New 
York City hospitals shared a similar experience of explosive 
VRE dissemination. Vancomycin-resistant enterococci were 
first identifted in two New York City hospitals in 1989; by 
1991 VRE had been reported from 38 hospitals; and by 1993 
VRE had been isolated from 65 hospitals in the city (97% 
of total).lO,ll By 1993,8.1% of 47,322 enterococcal isolates 
tested at 38 laboratories in New York City were identified 
as VRE.” 
In spite of the rapid emergence of VRE as a nosoco- 
mial pathogen and the dramatic increase in VRE prevalence, 
much of the epidemiology of VRE infection and colo- 
nization remains obscure. l2 Certain patient populations 
have been identified to be at increased risk for VRE colo- 
nization and infection, including critically ill patients or 
those with severe underlying disease or immunosuppres- 
sion (i.e., patients in intensive care, oncology, and trans- 
plantation units), patients who have had i&-a-abdominal 
or cardiothoracic surgical procedures or an indwelling 
urinary or central venous catheter, and patients who have 
had prolonged hospital stays or who have received multi- 
antimicrobial and/or vancomycin therapy.1,4,5,7-10,12,13 
Montefiore Medical Center is a 750-bed teaching 
hospital, with active intensive care, oncology, and trans- 
plantation units, that is located in the borough of the 
Bronx in New York City. Vancomycin-resistant entero- 
coccal isolates were first recovered at this institution in 
1991, and initial efforts at assessing VRE prevalence in the 
hospital were accomplished by monitoring the frequency 
of VRE isolates among the 50,000 sterile body fluid sam- 
ples (blood, cerebrospinal fluid, and other sterile body flu- 
ids, excluding urine or wound cultures) sent to the 
microbiology laboratory for culture on an annual basis. 
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There were three patients with VRE isolates in 1991, 11 in 
1992, and 40 in 1993. Thus, although the pattern of increas- 
ing frequency of VRE isolation was of concern, it was 
thought that the prevalence of VRE in the hospital was rel- 
atively low. Infection control activities were directed toward 
eradicating VRE and limiting the nosocomial transmission 
of VRE. Patients identified with VRE-positive sterile body 
fluid cultures were isolated in single rooms with glove and 
gown barrier precautions; strict adherence to handwash- 
ing and appropriate environmental decontamination were 
enforced. Early in 1994, a cluster of three patients with pos- 
itive blood cultures for VRE in one of the intensive care units 
prompted an extended investigation. Rectal swabs of 
patients in adjoining rooms at the time and those that had 
been in adjoining rooms and subsequently transferred to 
other wards identified seven more patients with stool cul- 
tures positive for VRE. However, pulsed-field gel electro- 
phoresis DNA typing of these isolates revealed that they 
were all genetically distinct. One possible explanation for 
the finding was that the prevalence of rectal colonization 
with VRE was so high in the hospital that a certain per- 
centage of patients chosen at random would have rectal 
swab cultures positive for VRE. 
Subsequently, a decision was made to conduct a VRE 
stool culture prevalence survey in the hospital with several 
objectives in mind. First, the survey sought to accurately 
assess the prevalence of VRE rectal colonization in the 
hospital and compare this method of surveillance to that 
of monitoring sterile body fluid cultures. Secondly, the sur- 
vey sought to assess the impact of antibiotic usage patterns 
on the prevalence of VRE rectal colonization in the hos- 
pital, using a design that controlled for a variety of risk fac- 
tors that have been reported to be associated with increased 
risk of VRE colonization or infection. Finally, the study was 
intended to serve as a model for use in other hospitals if 
the VRE rectal colonization survey was demonstrated to 
have utility. As a consequence, the study design sought to 
utilize a minimum of resources (cost and manpower) in 
accomplishing the survey and analyzing the data it gen- 
erated. This report presents a summary of the results of 
the study. 
SUBJECTS AND METHODS 
Patients chosen for inclusion in the study were randomly 
chosen on a rolling basis from admission lists, census lists, 
and pharmacy antibiotic usage lists at Montefiore Medical 
Center over a 9-week period from April to June 1994. 
Intensive care unit patients, oncology patients, and organ 
transplant patients were excluded, to control for the known 
increased risk for VRE infection or colonization that these 
patients experience. 1,9,12 In addition, since inclusion in 
the survey required verbal consent for a rectal swab, all 
pediatric and psychiatric patients were also excluded. As 
a result, prevalence estimates of VRE rectal colonization from 
this study should be considered minimal estimates and 
representative of adult patients. Patients chosen for inclusion 
were stratified into four groups: (1) those receiving no 
antibiotics, (2) those receiving broad-spectrum antibiotics 
not including either parenteral or oral vancomycin, (3) those 
receiving parenteral vancomycin with or without other 
broad-spectrum antibiotics and, (4) those receiving oral 
vancomycin. In group 1, the patients were further subdi- 
vided into those who had been hospitalized for 5 days or 
less and those who had been hospitalized for more than 5 
days. In groups 2 and 3, the patients were further subdi- 
vided into those who had received antibiotics for 5 days or 
less and those who had received antibiotics for more than 
5 days. For group 4, the mean duration of oral vancomycin 
therapy was 5.2 days (range 1-14 d). 
At the time of inclusion, chart review documented 
patient demographic data as well as any antibiotic usage, 
prior hospitalization, previous intensive care unit, oncol- 
ogy unit, or transplant unit hospitalization time, or nurs- 
ing home experience in the immediate 6-week period 
prior to inclusion, and a rectal swab was obtained for 
analysis. The final sample consisted of 131 patients cho- 
sen from the 4373 patients who occupied 539 beds dur- 
ing the study period (3% of total patients). 
Each rectal swab was subsequently incubated in sodium 
azid broth for 4 hours for enrichment.“* Aliquots of broth 
were then plated on Enterococcosel agar (Becton Dickinson 
Microbiology, Cockeysville, MD), containing 0 kg/mL, 
6 @mL, and 256 p.g/mL of vancomycin and Columbia 
colistin-nalidixic acid (CNA) agar and incubated for up to 
48 hours. Samples yielding typical enterococcal colonies 
on CNA agar and concomitant bile esculin positive colonies 
on Enterococcosel agar without vancomycin supplemen- 
tation were considered to be positive for enterococci. 
Samples yielding similar results on CNA agar and Entero- 
coccosel agar supplemented with 6 ug/mL or 256 yg/mL 
of vancomycin had three colonies subcultured to CNA 
agar and were identified as either enterococcal or non- 
enterococcal, using standard microbiologic techniques.15 
Enterococcal isolates were then speciated, using RapID SIR 
System analysis (Innovative Diagnostic Systems, Norcross, 
GA). Minimum inhibitory concentrations for ampicillin 
and vancomycin were determined by E-test (AB BIODISK, 
Piscataway, NJ), sensitivity to gentamicin and streptomycin 
was determined with a high level synergy broth screen (gen- 
tamicin 500 @mL and streptomycin 1000 pg/mL), l6 and 
teicoplanin sensitivity was determined using a teicoplanin 
disk for all VRE isolates. 
The proportion of patients with VRE isolates for each 
of the four patient groups and their subdivisions was 
calculated and expressed as a percentage. Pairwise 
comparisons of proportions were accomplished using a 
test of proportions. Comparisons of mean age, mean 
duration of hospitalization, and mean duration of anti- 
biotic therapy between groups and subdivisions were 
accomplished by Student’s t-test. Statistical analyses were 
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performed using the Primer of Biostatistics: The Program 
Computer Package (McGraw-Hill, New York, NY). 
The overall prevalence of VRE colonization in the 
hospital was estimated by extrapolating the VRE colonization 
rate in each patient group and subdivision to the actual 
number of patients with equivalent antibiotic histories 
among all patients hospitalized during the 9-week study 
period. For instance, the VRE stool colonization preva- 
lence rate observed among sampled patients who had not 
received antibiotic therapy and who had been hospitalized 
for 5 days or less was extrapolated to all hospital patients 
identified from pharmacy lists who had received no antibi- 
otics and had been hospitalized for 5 days or less during 
the 9-week period. This yielded an estimated hospital-wide 
number of VRE colonized patients among all patients hos- 
pitalized for 5 days or less who had received no antibiotics. 
This process was repeated for each of the seven patient cat- 
egories, and the sum of all estimated VRE colonized patients 
was divided by 4373 patients to approximate a hospital-wide 
VRE prevalence rate. 
The antibiotic experience of group 2 patients (those 
receiving broad-spectrum antibiotics exclusive of par- 
enteral or oral vancomycin) was further defined for pur- 
poses of extrapolation. The most commonly used antibiotics 
in this patient category included piperacillin, gentamicin, 
ciprofloxacin, and cephalosporins (cefoxitin, ceftriaxone, 
and ceftazidime), with at least 25% of patients having 
received each of these antibiotic categories. The risk of 
being VRE colonized as a result of exposure to each anti- 
biotic was estimated by calculating odds ratios (OR), with 
the following results: piperacillin OR = 1.1, gentamicin OR 
= 0.94, ciprofloxacin OR = 1.2, and cephalosporins (cefox- 
itin, ceftriaxone, and ceftazidime) OR = 2.6. Although the 
odds ratio for cephalosporins was not significantly differ- 
ent than 1 .O at the 0.05 level, the increased risk was con- 
sidered a trend, and exposure to broad-spectrum antibiotics 
was equated with exposure to cephalosporins (cefoxitin, 
ceftriaxone, and ceftazidime) when rates were extrapolated. 
Thus, the sample VRE colonization prevalence rates for 
group 2 patients were extrapolated only to hospital patients 
who had received either 5 or less days or more than 5 days 
of cefoxitin, ceftriaxone, or ceftazidime. 
RESULTS 
An enterococcal isolate was obtained from 99.2% (130/l 31) 
of patients in the sample. Forty-two of 13 1 (32.1%) sample 
patients were colonized with VRE: 41 of 42 (97.6%) VRE 
isolates were of the Van A phenotype, and only one (2.4%) 
was a Van B phenotype; 38 of 42 (90.4%) VRE isolates 
were Enterococcus faecium and 4 of 42 (9.6%) were 
Enterococcus faecalis. All VRE isolates had high-level 
resistance to ampicillin (MIC > 256 Pg/rnL) and 60 to 72% 
exhibited high-level resistance to gentamicin and/or strep- 
tomycin. This characterization of rectal-colonizing VRE 
isolates indicated that they were similar to VRE isolates 
obtained from sterile body fluid cultures at Montefiore 
Medical Center. Sterile body fluid isolates are also over- 
whelmingly E. faecium, are overwhelmingly of the Van A 
phenotype, and exhibit similar antibiotic sensitivity patterns. 
Table 1 presents the percentage of patients with positive 
rectal swab cultures for VRE stratitied by antibiotic category 
and subdivided by duration of hospitalization or duration 
of antibiotic course (5 5 d or > 5 d). Patients who were 
hospitalized and who did not receive antibiotics were not 
colonized with VRE regardless of length of hospital stay. It 
is important to note that some of these patients had been 
hospitalized for up to 44 days. The percentage of VRE 
colonization among patients who had received broad- 
spectrum antibiotics without either parenteral or oral 
vancomycin ranged between 31.2% and 37.5%. The pro- 
portion of VRE colonized patients receiving broad-spectrum 
antibiotics was not significantly different among patients 
receiving 5 days or less of therapy versus those receiving 
more than 5 days of therapy (P > 0.05). The proportion of 
VRE colonized patients in the category of broad-spectrum 
antibiotics without vancomycin was significantly higher than 
among patients receiving no antibiotics (p < 0.001). Patients 
receiving parenteral vancomycin with or without broad- 
spectrum antibiotics for 5 days or less had a VRE colonization 
rate of 28.6%, which was not significantly different from 
that of either of the two groups of patients receiving broad- 
spectrum antibiotics (P > 0.05). The proportion of VRE co10 
nized patients among patients receiving parenteral 
vancomycin for 5 days or less with or without broad- 
spectrum antibiotics was significantly higher than among 
patients receiving no antibiotics (p < 0.001). Interestingly, 
the proportion of VRE colonization among patients receiv- 
ing parenteml vancomycin for more than 5 days with or with- 
out broad-spectrum antibiotics was 64.0%, which was 
significantly higher than that of patients receiving no anti- 
biotics, patients receiving broad-spectrum antibiotics with- 
out parenteral or oral vancomycin, and patients receiving 
parenteral vancomycin for 5 days or less with or without 
broad-spectrum antibiotics (P = 0.002, P = 0.05, and P = 0.03, 
respectively). Finally, patients receiving oral vancomycin 
had a VRE prevalence rate of 75.0%, which was not sig- 
nificantly greater than for patients receiving parenteral 
vancomycin for more than 5 days with or without broad- 
spectrum antibiotics (P = 0.77) but was significantly 
greater than for all other patient categories (P < 0.03). 
The mean age of patients in each patient category and 
subcategory did not differ signiticantly (P > 0.05). The aver- 
age duration of hospital stay prior to inclusion in the study 
differed significantly among major patient categories and 
subcategories: patients receiving parenteral vancomycin 
with or without broad-spectrum therapy were hospitalized 
longer than patients receiving broad-spectrum antibiotics 
without vancomycin, who were hospitalized longer than 
patients receiving no antibiotics (P I 0.03). However, 
increasing duration of hospitalization prior to inclusion did 
not appear to be clearly associated with increased VRE 
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Table 1. Vancomycin-Resistant Enterococcal Rectal Colonization Rates Stratified according to Antibiotic Use 
Sample 
Size 
(n = 131) Patient Category 
Mean 
Age (yr 
Mean Mean Percentage 
Duration of Duration of of Patients 
Hospitalization* (d) Antibiotic Therapy* (4 with VRE 
20 
21 
16 
16 
21 
25 
12 
No antibiotics 55 days 
No antibiotics x5 days 
Broad-spectrum antibiotics 
without vancomycin ‘5 days 
Broad-spectrum antibiotics 
without vancomycin x5 days 
Parenteral vancomycin 
with/without other antibiotics _<5 days 
Parenteral vancomycin 
with/without other antibiotics >5 days 
Oral vancomycin 
59.6 1.6 0.0 
70.5 11.6 0.0 
66.0 4.1 3.1 31.2 
70.8 15.1 12.3 37.5 
68.2 7.3 2.6 28.6 
66.8 19.5 10.2 64.0 
75.0 
*Prior to time of inclusion in study. 
colonization rates, except among patients who received 
parenteral vancomycin with or without other antibiotic 
therapy Among the patient categories of broad-spectrum 
antibiotics without parenteral or oral vancomycin and 
parenteral vancomycin with or without broad-spectrum 
antibiotics, the average duration of antibiotic therapy prior 
to inclusion did not differ significantly among patients 
receiving therapy for 5 days or less (3.1 vs. 2.6 d, P = 0.20) 
or among patients receiving therapy for more than 5 days 
(12.3 vs. 10.2 d, P = 0.27). 
Examination of data concerning prior hospitalization 
and antibiotic use for the 6week period prior to inclusion 
in the survey indicated that 20.6% of patients (27/131) had 
a history of prior antibiotic use and that 16.8% of patients 
(22/131) had a history of prior hospitalization. The propor- 
tion of patients with a prior history of antibiotic use was 
not significantly different among the patient categories of 
no antibiotics, broad-spectrum antibiotics without vanco- 
mycin, and parenteral vancomycin with or without other 
antibiotics (22.0%, 31.3%, and 28.3%, respectively, P > 
0.53). Similarly, the proportion of patients with a prior his- 
tory of hospitalization was not significantly different among 
the patient categories of no antibiotics, broad-spectrum anti- 
biotics without vancomycin, and parenteral vancomycm 
with or without other antibiotics (15.8%, 12.5%, and 
26.1%, respectively, P > 0.24). No patient with a prior his- 
tory of hospitalization had spent time in an intensive care 
unit, oncology unit, or organ transplant unit. Finally, the 
proportion of patients receiving cephalosporins (cefoxitin, 
ceftriaxone, and ceftazidime) among patients receiving 
parenteral vancomycin for 5 days or less was not sign& 
cantly different from that among patients receiving vanco- 
mycin for more than 5 days (20.0% vs. 32.0%, P = 0.51). 
Extrapolation of VRE prevalence rates in each patient 
category to the actual number of patients who had equiv- 
alent antibiotic usage patterns among the 4373 total 
patients admitted to the 539 beds during the 9-week 
period indicates that 269 of the 4373 patients (6.2%) could 
be expected to be colonized with VRE (see Table 1). In com- 
parison, monitoring of sterile body fluid cultures for VRE 
detected only 18 patients either infected or colonized 
with VRE during the same period (0.42%). 
DISCUSSION 
The results of this survey clearly document that monitor- 
ing of sterile body fluid cultures for VRE can be an insen- 
sitive way to assess hospital-wide VRE prevalence and 
suggest that periodic rectal swab culture surveys may more 
accurately determine the prevalence of VRE. These results 
are consistent with a recent report from an SOO-bed hospital 
in Belgium, where no VRE had been isolated from clinical 
samples, but a rectal swab culture survey determined that 
3.5% of patients had rectal colonization with VRE.” 
The utility of a rectal swab culture survey for VRE at 
Montefiore Medical Center is underscored by the dra- 
matic way in which the results altered the perception of 
VRE prevalence in the hospital. This survey documented 
that VRE colonization of patients at the hospital was an 
endemic problem, rather than an unusual or infrequent 
event, as suggested by surveillance of sterile body fluid 
cultures for VRE. As a consequence, it became clear that 
infection control interventions designed to eliminate VRE 
from the hospital were no longer feasible or practical. For 
instance, adherence to infection control guidelines 
designed to eliminate VRE from the hospital would virtually 
require that all patients be cultured for VRE, and that the 
estimated 1500 patients per year identified as being VRE 
colonized be isolated to single rooms or be cohorted to 
isolation rooms until such time that they are demon- 
strated to be free of VRE colonization.12 Such activities 
would be considered impractical in most large hospitals. 
Alternatively, infection control activities designed to iso- 
late only patients with positive sterile body fluid cultures 
for VRE would also be ineffective in controlling the pres- 
ence of VRE in the hospital. 
As a result, infection control activities now focus on 
practices consistent with the prevalence of VRE in the hos 
pital. For instance, isolation efforts are maximized when 
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patients with VRE isolation from sterile body fluid cultures REFERENCES 
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